Monday August 22, 2022
Notice of Interim Results and Investor Presentation
Destiny Pharma plc (“Destiny Pharma” or the “Company”) Notice of Interim Results and Investor Presentation Brighton, United Kingdom ‐ 22 August 2022 ‐ Destiny Pharma plc (AIM: DEST), a clinical […]
Thursday July 28, 2022
Chair’s Investor Update
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Chair’s Investor Update Brighton, United Kingdom – 28 July 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused […]
Tuesday July 26, 2022
Publication of new data on NTCD-M3
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Publication of new data on NTCD-M3 confirms potential as an effective treatment for prevention of C. difficile infections Brighton, United Kingdom – 26 July 2022 […]
Tuesday July 19, 2022
Positive update from US FDA on XF-73 Phase 3
Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma announces positive update from US FDA on XF-73 Phase 3 development plans FDA clarifies Phase 3 and US registration pathway […]
Tuesday July 12, 2022
Destiny Pharma receives award from the Cystic Fibrosis Foundation
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma receives award from the Cystic Fibrosis Foundation Study to investigate potential of XF-73 to treat MRSA infection in people with […]
Thursday July 7, 2022
Destiny Pharma announce publication of XF-73 drug synergy data
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma announces publication of XF-73 drug synergy data XF-73 shown to enhance the activity of two antibacterial drugs Findings may lead […]
Tuesday July 5, 2022
Destiny Pharma announces start of a new XF-73 research programme
Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma announces start of a new XF-73 research programme Aim to test XF-73 as a potential preventive medicine for Oral Mucositis […]
Friday May 27, 2022